Author(s): Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, et al.
Background:Short-term studies suggest that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown. We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP.
Methods:117 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial. IGIV-C (Gamunex) or placebo was given every 3 weeks for up to 24 weeks in an initial treatment period, and patients who did not show an improvement in INCAT disability score of 1 point or more received the alternate treatment in a crossover period. The primary outcome was the percentage of patients who had maintained an improvement from baseline in adjusted INCAT disability score of 1 point or more through to week 24. Patients who showed an improvement and completed 24 weeks of treatment were eligible to be randomly re-assigned in a blinded 24-week extension phase. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00220740.
Findings:During the first period, 32 of 59 (54%) patients treated with IGIV-C and 12 of 58 (21%) patients who received placebo had an improvement in adjusted INCAT disability score that was maintained through to week 24 (treatment difference 33.5%, 95% CI 15.4-51.7; p=0.0002). Improvements from baseline to endpoint were also recorded for grip strength in the dominant hand (treatment difference 10.9 kPa, 4.6-17.2; p=0.0008) and the non-dominant hand (8.6 kPa, 2.6-14.6; p=0.005). Results were similar during the crossover period. During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011). The incidence of serious adverse events per infusion was 0.8% (9/1096) with IGIV-C versus 1.9% (11/575) with placebo. The most common adverse events with IGIV-C were headache, pyrexia, and hypertension.
Interpretation:This study, the largest reported trial of any CIDP treatment, shows the short-term and long-term efficacy and safety of IGIV-C and supports use of IGIV-C as a therapy for CIDP.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/18178525
Author(s): Caro XJ, Winter EF, Dumas AJ
Author(s): Bednarík J, Kadanka Z
Author(s): Ahmed AR, Dahl MV
Author(s): Gurcan HM, Ahmed AR
Author(s): Katz U, Achiron A, Sherer Y, Shoenfeld Y
Author(s): Orbach H, Katz U, Sherer Y, Shoenfeld Y
Author(s): Ruetter A, Luger TA
Author(s): Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP
Author(s): Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, et al.
Author(s): Wittstock M, Benecke R, Zettl UK
Author(s): Brannagan TH 3rd
Author(s): Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, et al.
Author(s): Pedrosa RP, Barros IM, Drager LF, Bittencourt MS, Medeiros AK, et al.
Author(s): Russell IJ, Larson AA
Author(s): Jessop DS, Renshaw D, Larsen PJ, Chowdrey HS, Harbuz MS
Author(s): Larsen PJ, Jessop D, Patel H, Lightman SL, Chowdrey HS
Author(s): Donaldson CC, Snelling LS, MacInnis AL, Sella GE, Mueller HH
Author(s): Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, et al.
Author(s): Kim L, Lipton S, Deodhar A
Author(s): Moldofsky HK
Author(s): Moldofsky H, Inhaber NH, Guinta DR, Varez-Horine SB
Author(s): Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, et al.
Author(s): Rosenfeld VW, Rutledge DN, Stern JM
Author(s): Ahles TA, Khan SA, Yunus MB, Spiegel DA, Masi AT
Author(s): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al.
Author(s): Katz RS, Wolfe F, Michaud K
Author(s): Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, et al.
Author(s): Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, et al.
Author(s): Giovengo SL, Russell IJ, Larson AA
Author(s): Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L
Author(s): White KP, Harth M
Author(s): Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, et al.
Author(s): Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF
Author(s): Goldenberg DL, Burckhardt C, Crofford L
Author(s): Carville SF, Choy EH
Author(s): Perrot S, Russell IJ
Author(s): Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, et al.
Author(s): Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, et al.
Author(s): Kuwahara M, Suzuki S, Takada K, Kusunoki S
Author(s): Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS
Author(s): Zhang HL, Zhang XM, Mao XJ, Deng H, Li HF, et al.
Author(s): Eldar AH, Chapman J
Author(s): Dalakas MC; Medscape
Author(s): Boukhris S, Magy L, Khalil M, Sindou P, Vallat JM
Author(s): Westblad ME, Forsberg A, Press R
Author(s): Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, et al.
Author(s): Latov N
Author(s): Joint Task Force of the EFNS and the PNS
Author(s): Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, et al.
Author(s): Magda P, Latov N, Brannagan TH 3rd, Weimer LH, Chin RL, et al.
Author(s): Thaisetthawatkul P, Logigian EL, Herrmann DN
Author(s): Saperstein DS, Katz JS, Amato AA, Barohn RJ
Author(s): Barohn RJ, Kissel JT, Warmolts JR, Mendell JR
Author(s): Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al.
Author(s): McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, et al.
Author(s): Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, et al.
Author(s): Magy L, Mathis S, Vallat JM
Author(s): Rajabally YA, Nicolas G, Piéret F, Bouche P, Van den Bergh PY
Author(s): Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA
Author(s): Dalakas MC
Author(s): Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, et al.
Author(s): Bedi G, Brown A, Tong T, Sharma KR
Author(s): Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, et al.
Author(s): Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RA
Author(s): Bright RJ, Wilkinson J, Coventry BJ
Author(s): Boukhris S, Magy L, Gallouedec G, Khalil M, Couratier P, et al.
Author(s): Dionne A, Nicolle MW, Hahn AF
Author(s): Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D